Abstract: Objective To analyze anemia caused by finerenone based on a case report in order to provide a reference for rational use of finerenone. Methods The treatment process, risk factors, possible mechanism and treatment regimens related to a diabetic kidney disease (DKD) patient with hemoglobin decline that was believed to have been caused by finerenone were analyzed based on research currently available. Results A DKD patient experienced hemoglobin decline after taking finerenone for four months. With an increase in drug dosage, the patient’s hemoglobin continued to decrease. With a Naranjo’s score of 8, the patient’s anemia was considered to have been caused by finerenone. After the patient discontinued the drug, hemoglobin gradually recovered during follow-up. Conclusion Clinicians should be alert to finerenone-induced anemia. Early identification and immediate interventions are crucial to preventing serious adverse drug reactions.

Key words: Finerenone, Diabetic Kidney Disease, Hemoglobin, Anemia, Adverse Drug Reactions